文献速递姑息放疗与转移瘤放疗物理与技术

寡转移性骨转移立体定向消融放疗:BONY-M 2期试验1年随访

Stereotactic Ablative Radiation Therapy of Bone Metastases in an Oligometastatic Setting: One-Year Follow-Up of the BONY-M Phase 2 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-07-24

BONY-M是一项单臂2期多中心试验,评估30或37.5 Gy分3次SABR治疗寡转移患者无并发症骨转移的疗效与毒性。67例患者共79处骨转移,1年中心评估局部控制率为93.1%,3级骨折发生率为3.3%,症状性骨骼事件发生率为6.0%,1年总生存率为92%。

要点

  • SABR 30或37.5 Gy分3次治疗无并发症骨寡转移,1年局部控制率达93.1%。
  • 3级骨折发生率3.3%,症状性骨骼事件发生率6.0%,毒性可接受。
  • 1年总生存率92%,无进展生存率62%,中位随访12.1个月。

核心结论

  • SABR 30或37.5 Gy分3次治疗寡转移患者无并发症骨转移,1年局部控制率有前景且毒性可接受。

研究设计与样本

  • BONY-M为单臂2期多中心试验(NCT05101824),纳入67例寡转移患者共79处骨转移(31处脊柱、48处非脊柱),分布于挪威和丹麦。
  • SABR方案为30或37.5 Gy分3次,允许最多5个活动性转移灶且全部接受消融治疗。
  • 主要终点为1年局部控制率,次要终点包括毒性(CTCAE)和生存。

主要发现

  • 1年中心评估局部控制率为93.1%(95%CI 87.3-99.2)。
  • 1年内2例发生3级骨折,发生率为3.3%(95%CI 0%-7.8%);4例发生症状性骨骼事件,发生率为6.0%(95%CI 0.0%-11.6%)。
  • 1年总体中心评估骨折率为9.9%(95%CI 2.6%-16.7%;n=7)。
  • 中位随访12.1个月,1年总生存率为92%,无进展生存率为62%。

临床怎么用

  • 对寡转移患者无并发症骨转移,可考虑SABR 30或37.5 Gy分3次治疗,需关注骨折和症状性骨骼事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: SABR is increasingly applied to treat oligometastatic disease (OMD). As patients may be asymptomatic, severe toxicity must be carefully balanced with effect in this setting. The BONY-M trial aimed to determine the efficacy and toxicity after SABR of uncomplicated bone metastases in patients with OMD. METHODS AND MATERIALS: The BONY-M trial is a single-arm phase 2 multicenter trial (clinicaltrials.gov ID: ClinicalTrials.gov ID NCT05101824) investigating SABR of uncomplicated bone oligometastases with 30 or 37.5 Gy in 3 fractions. Patients with OMD and ≥1 mechanical stable bone metastasis without epidural invasion were eligible for inclusion. Up to 5 active metastatic lesions were allowed if all received ablative therapy. The primary endpoint was 1-year local control rate (LCR). Secondary endpoints included toxicity (CTCAE) and survival. RESULTS: The BONY-M trial included 67 patients with 79 bone metastases (31 spine, 48 nonspine) in Norway and Denmark. The 1-year centrally assessed LCR rate was 93.1% (95% confidence interval [CI], 87.3-99.2). Two patients had grade 3 fractures within 1 year, 3.3% (95% CI, 0%-7.8%) and 4 patients had a symptomatic skeletal event, 6.0% (95% CI, 0.0%-11.6%). The 1-year overall centrally assessed fracture rate was 9.9% (95% CI, 2.6%-16.7%; n = 7). The 1-year overall and progression-free survival were 92% and 62% after a median follow-up of 12.1 months. CONCLUSION: SABR of uncomplicated bone metastases with 37.5 or 30 Gy in 3 fractions showed a promising 1-year LCR with an acceptable toxicity profile in patients with OMD.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Spindler NJ, Felter MVO, Hansen O, et al. Stereotactic Ablative Radiation Therapy of Bone Metastases in an Oligometastatic Setting: One-Year Follow-Up of the BONY-M Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 40714134. doi:10.1016/j.ijrobp.2025.07.1419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。